Ilke Nalbantoglu, MD
Associate Professor of PathologyDownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileContact Info
About
Titles
Associate Professor of Pathology
Appointments
Pathology
Associate Professor on TermPrimary
Other Departments & Organizations
- Gastrointestinal (GI) & Liver Pathology
- Pathology
- Surgical Pathology
- Yale Medicine
Education & Training
- MD
- Ege University School of Medicine, M.D.
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor Profile
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Ilke Nalbantoglu's published research.
Publications Timeline
A big-picture view of Ilke Nalbantoglu's research output by year.
Joanna Gibson, MD, PhD
Dhanpat Jain, MD
Joseph Paul Eder, MD
Karin Finberg, MD, PhD
Michael Cecchini, MD
Xuchen Zhang, MD, PhD
46Publications
1,926Citations
Publications
2024
Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease
Stokes N, Patil A, Adeyi O, Bhalla A, Brown I, Byrnes K, Calderaro J, Chen D, Chen W, Cooper C, Dhall D, Frankel W, Gooch G, Gonzalez R, Hammer S, Hale G, Lagana S, McKenzie C, Allende D, Moreira R, Nakhleh R, Nalbantoglu I, Pai R, Salomao M, Schaeffer D, Shih A, Shin J, Simoes C, Vij M, Rela M, Xue Y, Yantiss R, Sabatto B, Graham R. Validation of Metallothionein Immunohistochemistry as a Highly Sensitive Screening Test for Wilson Disease. Modern Pathology 2024, 38: 100628. PMID: 39384020, DOI: 10.1016/j.modpat.2024.100628.Peer-Reviewed Original ResearchCitationsConceptsWilson's diseaseHistological featuresRare autosomal recessive conditionChronic cholestatic diseaseProtean clinical manifestationsEvaluation of patientsAutosomal recessive conditionSensitive screening testCase of WDCost-effective screening toolRoutine histologic sectionsMedian ageNeedle biopsyCholestatic diseasesWD patientsFibrosis stageClinical manifestationsHistopathological patternsATP7B mutationsHistological patternWD diagnosisTissue specimensAssessed patientsImmunohistochemistryMasson's trichromeValidation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I, Zhang X, Curl E, Taliano R, Kim T, Torbenson M, Glickman J, Resnick M, Patel N, Taylor C, Bedossa P, Montalto M, Beck A, Wack K. Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials. The Journal Of Pathology Clinical Research 2024, 10: e12395. PMID: 39294925, PMCID: PMC11410674, DOI: 10.1002/2056-4538.12395.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsClinical trialsAssessment of disease activityOverall percent agreementLiver biopsyDisease activityPathological assessmentWashout periodHistological assessmentEndpoint assessmentGold standardPercent agreementScoring systemExpert pathologistsSteatohepatitisAverage agreementDigital scoresPathologistsTrials
2023
Clinical and Pathological Correlation in Concomitant Celiac Disease and Eosinophilic Esophagitis Suggests Separate Etiologies
Castrodad-Rodríguez C, Cheng J, Westerhoff M, Liang G, Lin J, Nalbantoglu I, Hu S, Sekhri R, Panarelli N. Clinical and Pathological Correlation in Concomitant Celiac Disease and Eosinophilic Esophagitis Suggests Separate Etiologies. International Journal Of Surgical Pathology 2023, 32: 27-34. PMID: 37050846, DOI: 10.1177/10668969231167526.Peer-Reviewed Original ResearchCitationsConceptsConcomitant celiac diseaseEosinophilic esophagitisStudy patientsCeliac diseasePeak esophageal eosinophil countsCeliac disease symptomsMost study patientsGluten-free dietPatients meeting criteriaDisease-related symptomsEsophageal eosinophil countsDuodenal histologyAtopic conditionsEsophageal symptomsHistological severitySubepithelial fibrosisEosinophil countMarsh IIPathological featuresPathological correlationEsophagitisSeparate etiologiesPatientsMeeting criteriaControl groupApproach to the liver biopsy diagnosis of adult cholangiopathies
Nalbantoglu I, Misdraji J. Approach to the liver biopsy diagnosis of adult cholangiopathies. Diagnostic Histopathology 2023, 29: 23-35. DOI: 10.1016/j.mpdhp.2022.10.004.Commentaries, Editorials and LettersAltmetricConceptsPrimary biliary cholangitisChronic biliary disordersBiliary cholangitisBiliary disordersPrimary sclerosing cholangitisLiver biopsy diagnosisAutoimmune hepatitisSclerosing cholangitisAdult patientsInflammatory variantClinical featuresHistologic featuresHistologic findingsBiopsy diagnosisDifferential diagnosisCholangitisCorrect diagnosisCholangiopathyClinical informationCareful assessmentDiagnosisDisordersWide spectrumVast majorityHepatitis
2022
Liver allograft findings of donation after cardiac death versus brain death in recipients with hepatitis C related cirrhosis: a matched histologic comparison
Byrnes K, Vachharajani N, Doyle MM, Nalbantoglu I. Liver allograft findings of donation after cardiac death versus brain death in recipients with hepatitis C related cirrhosis: a matched histologic comparison. Human Pathology 2022, 122: 25-31. PMID: 35085598, DOI: 10.1016/j.humpath.2022.01.005.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBiliary complicationsDCD casesLiver allograftsCardiac deathHistologic featuresBrain death (DBD) recipientsDCD liver allograftsPostoperative biliary complicationsBile duct injuryCold ischemia timeHepatitis C virusOrgan transplantation increasesBiliary alterationsDBD recipientsDCD allograftsDCD recipientsPortal edemaDuct injuryGraft survivalHepatitis CPortal inflammationOverall survivalTransplantation increasesLiver biopsyClinical outcomes
2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan
Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. The Lancet Oncology 2021, 22: 306-307. PMID: 33662283, DOI: 10.1016/s1470-2045(20)30683-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsGastric Xanthoma
Abu‐Alreesh S, Rosen D, Nalbantoglu I, Arbizu RA. Gastric Xanthoma. Journal Of Pediatric Gastroenterology And Nutrition 2021, 73: e26-e26. PMID: 33605661, DOI: 10.1097/mpg.0000000000003085.Peer-Reviewed Case Reports and Technical NotesCitationsAltmetricMeSH KeywordsApobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer
Blanc V, Riordan JD, Soleymanjahi S, Nadeau J, Nalbantoglu I, Xie Y, Molitor EA, Madison BB, Brunt EM, Mills JC, Rubin DC, Ng I, Ha Y, Roberts LR, Davidson NO. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer. Journal Of Clinical Investigation 2021, 131 PMID: 33445170, PMCID: PMC7773377, DOI: 10.1172/jci138699.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHuman hepatocellular cancerHigh-fructose dietHepatocellular cancerNonalcoholic fatty liver diseaseFatty liver diseaseExpression of mRNALipogenic gene expressionSpontaneous fibrosisAdvanced fibrosisLiver diseaseLiver functionHepatic steatosisInflammatory pathwaysInflammatory responseFed chowLong-term effectsTissue microarrayHepatic proliferationMRNA expressionFactor overexpressionReduced survivalFibrosisOxidative stressExtracellular matrix organizationSteatosis
2020
Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft
González IA, Hartley CP, Nalbantoglu I. Recurrent Autoimmune Hepatitis and De Novo Autoimmune Hepatitis in the Liver Allograft. American Journal Of Clinical Pathology 2020, 155: 435-445. PMID: 33252121, DOI: 10.1093/ajcp/aqaa147.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDe novo AIHOrthotopic liver transplantDe novo autoimmune hepatitisAutoimmune hepatitisNovo autoimmune hepatitisRecurrent AIHRecurrent autoimmune hepatitisGraft survivalPresentation of AIHModerate portal inflammationOverall graft survivalAggressive clinical courseSubmassive necrosisLiver allograftsLiver transplantPortal inflammationSevere hepatitisAggressive treatmentAdvanced fibrosisClinical courseClinicopathologic characteristicsFemale predominanceSevere inflammationHepatitisPatientsPrimary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation
Aranake-Chrisinger J, Dassopoulos T, Yan Y, Nalbantoglu I. Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation. World Journal Of Gastroenterology 2020, 26: 4126-4139. PMID: 32821074, PMCID: PMC7403798, DOI: 10.3748/wjg.v26.i28.4126.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsInflammatory bowel diseaseOrthotopic liver transplantationPSC-IBD patientsUlcerative colitisCrohn's diseasePSC-UCLiver transplantationHistologic featuresLeft colonPSC-UC patientsPrimary sclerosing cholangitisRight-sided diseaseWarrants clinical attentionDifferent disease phenotypesIBD durationIBD patientsPSC patientsSclerosing cholangitisUC patientsActive inflammationRectal involvementBowel diseaseClinical featuresPSC diagnosisLess steroids
Clinical Trials
Current Trials
Wilson Disease Registry
HIC ID1609018429REGRoleSub InvestigatorPrimary Completion Date10/01/2022Recruiting ParticipantsGenderBoth
Clinical Care
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor Profile